美洛昔康联合吉非替尼治疗食管癌的有效性及安全性分析

目的:探究美洛昔康联合吉非替尼治疗食管癌的有效性及安全性。方法:前瞻性选取2016年8月至2018年6月我院收治的88例食管癌患者作为研究对象，采用随机数字表法，分为对照组（44例）和观察组（44例），对照组给予吉非替尼治疗，观察组在对照组的基础上给予美洛昔康治疗，均治疗4个疗程，每个疗程21 d。疗程结束后采用实体瘤疗效评价标准（RECIST）评价短期治疗效果，采用Kaplan-Meier生存曲线分析治疗效果，并采用常见不良反应事件评价标准（CTCAE）评价药物安全性，并比较。结果:观察组患者的临床总有效率、疾病控制率分别为84.09%、90.91%，明显高于对照组患者的63.64%、75.00%，差异均有统计学意义（P＜0.05）。Kaplan-Meier 生存分析显示，观察组的平均生存时间和中位生存时间均明显高于对照组，差异有统计学意义（P＜0.05）；且经Log-Ｒank（Mantel-Cox）检验显示，观察组的生存率明显高于对照组，差异有统计学意义（P＜0.05）。两组患者恶心呕吐、骨髓抑制、腹泻、皮疹等主要不良反应发生率比较，差异均无统计学意义（P＞0.05）；且两组患者不良反应均为Ⅰ-Ⅱ级，症状较轻，对症治疗后，症状皆可缓解。结论:美洛昔康联合吉非替尼治疗食管癌的有效性较好，且不良反应少，安全性高，值得临床推广使用。

Efficacy and safety of meloxicam combined with gefitinib in the treatment of esophageal cancer

Objective:To explore the efficacy and safety of meloxicam combined with gefitinib in the treatment of esophageal cancer.Methods:88 patients with esophageal cancer admitted to our hospital from August 2016 to June 2018 were prospectively selected as the research object,and divided them into control group(44 cases) and observation group(44 cases) by random number table method.The control group was treated with gefitinib,while the observation group was treated with meloxicam on the basis of the control group,with four courses of treatment each.The course of treatment was 21 days.After treatment,the short-term therapeutic effect of RECIST was used.The therapeutic effect was analyzed by Kaplan-Meier survival curve,and the drug safety was evaluated by CTCAE.Results:The total effective rate and disease control rate in the observation group were 84.09% and 90.91% respectively,which were significantly higher than those in the control group(63.64% and 75.00%,respectively),with statistical significance(P＜0.05).Kaplan-Meier survival analysis showed that the average survival time and median survival time of the observation group were significantly higher than those of the control group(P＜0.05),and Log-Rank(Mantel-Cox) test showed that the survival rate of the observation group was significantly higher than that of the control group(P＜0.05).There was no significant difference in the incidence of nausea and vomiting,bone marrow suppression,diarrhea,rash and other major adverse reactions between the two groups(P>0.05),and the adverse reactions in both groups were grade Ⅰ to Ⅱ,with mild symptoms.After symptomatic treatment,the symptoms could be alleviated.Conclusion:Meloxicam combined with gefitinib is effective in the treatment of esophageal cancer,with fewer adverse reactions and high safety,which is worthy of clinical application.